Japan Society of Hepatology guidelines for sarcopenia in Recommendation from the working group for creation

Hepatology Research 46, 951-963

DOI: 10.1111/hepr.12774

Citation Report

#	Article	IF	CITATIONS
1	Sarcopenia predicts minimal hepatic encephalopathy in patients with liver cirrhosis. Hepatology Research, 2017, 47, 1359-1367.	3.4	78
2	Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 915-925.	7.3	150
3	Clinical utility of bioimpedance analysis in liver cirrhosis. Journal of Hepato-Biliary-Pancreatic Sciences, 2017, 24, 409-416.	2.6	28
4	Efficacy of branched-chain amino acid supplementation and walking exercise for preventing sarcopenia in patients with liver cirrhosis. European Journal of Gastroenterology and Hepatology, 2017, 29, 1416-1423.	1.6	113
5	Changes in skeletal muscle mass after endoscopic treatment in patients with esophageal varices. Medicine (United States), 2017, 96, e7377.	1.0	1
6	Effect of psoas muscle mass after endoscopic therapy for patients with esophageal varices. Medicine (United States), 2017, 96, e6868.	1.0	3
7	Significance of psoas muscle thickness as an indicator of muscle atrophy in patients with hepatocellular carcinoma treated with sorafenib. Molecular and Clinical Oncology, 2017, 7, 449-453.	1.0	26
8	Clinical Outcomes of Living Liver Transplantation According to the Presence of Sarcopenia as Defined by Skeletal Muscle Mass, Hand Grip, and Gait Speed. Transplantation Proceedings, 2017, 49, 2144-2152.	0.6	41
9	Prognostic significance of low skeletal muscle mass compared with protein–energy malnutrition in liver cirrhosis. Hepatology Research, 2017, 47, 1042-1052.	3.4	14
10	Relationship between skeletal muscle mass and liver fibrosis markers for patients with hepatitis C virus related liver disease. Medicine (United States), 2017, 96, e8761.	1.0	4
11	Impact of Virtual Touch Quantification in Acoustic Radiation Force Impulse for Skeletal Muscle Mass Loss in Chronic Liver Diseases. Nutrients, 2017, 9, 620.	4.1	3
12	Predictors Associated with Increase in Skeletal Muscle Mass after Sustained Virological Response in Chronic Hepatitis C Treated with Direct Acting Antivirals. Nutrients, 2017, 9, 1135.	4.1	11
13	Sarcopenia Impairs Prognosis of Patients with Hepatocellular Carcinoma: The Role of Liver Functional Reserve and Tumor-Related Factors in Loss of Skeletal Muscle Volume. Nutrients, 2017, 9, 1054.	4.1	44
14	Comparison of Prognostic Impact between the Child-Pugh Score and Skeletal Muscle Mass for Patients with Liver Cirrhosis. Nutrients, 2017, 9, 595.	4.1	14
15	Nutritional Status in Liver Cirrhosis. , 2017, , .		1
16	Sarcopenia is a predictive factor for intestinal resection in admitted patients with Crohn's disease. PLoS ONE, 2017, 12, e0180036.	2.5	92
17	Compensating effect of minor portal hypertension on the muscle mass loss-related poor prognosis in cirrhosis. International Journal of Medical Sciences, 2017, 14, 804-810.	2.5	1
18	Implication of Psoas Muscle Index on Survival for Hepatocellular Carcinoma Undergoing Radiofrequency Ablation Therapy. Journal of Cancer, 2017, 8, 1507-1516.	2.5	29

#	Article	IF	CITATIONS
19	Impact of sarcopenic overweight on the outcomes after living donor liver transplantation. Hepatobiliary Surgery and Nutrition, 2017, 6, 367-378.	1.5	22
20	Impact of myosteatosis on skeletal muscle volume loss in patients with chronic liver disease. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1659-1666.	2.8	34
21	Decreased the creatinine to cystatin C ratio is a surrogate marker of sarcopenia in patients with type 2 diabetes. Diabetes Research and Clinical Practice, 2018, 139, 52-58.	2.8	108
22	Proposal for new selection criteria considering preâ€transplant muscularity and visceral adiposity in living donor liver transplantation. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 246-254.	7.3	54
23	Relative changes in handgrip strength and skeletal muscle volume in patients with chronic liver disease over a 2â€year observation period. Hepatology Research, 2018, 48, 502-508.	3.4	14
24	Skeletal muscle fat deposition is associated with hepatocellular carcinoma development in patients with chronic liver disease. Nutrition, 2018, 54, 83-88.	2.4	15
25	Application of transcutaneous ultrasonography for the diagnosis of muscle mass loss in patients with liver cirrhosis. Journal of Gastroenterology, 2018, 53, 652-659.	5.1	16
26	Impact of muscle volume and muscle function decline in patients undergoing surgical resection for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1271-1276.	2.8	21
27	Changes in liver function and body composition by directâ€acting antiviral therapy for hepatitis C virus infection. Hepatology Research, 2018, 48, 337-344.	3.4	28
28	Loss of skeletal muscle mass in patients with chronic liver disease is related to decrease in bone mineral density and exercise tolerance. Hepatology Research, 2018, 48, 345-354.	3.4	9
29	Health-Related Quality of Life in Chronic Liver Diseases: A Strong Impact of Hand Grip Strength. Journal of Clinical Medicine, 2018, 7, 553.	2.4	21
30	The association between sarcopenia and decorin, an exerciseâ€induced myokine, in patients with liver cirrhosis: a pilot study. JCSM Rapid Communications, 2018, 1, 1-10.	1.6	8
31	Effects of inâ€hospital exercise on sarcopenia in hepatoma patients who underwent transcatheter arterial chemoembolization. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 580-588.	2.8	41
32	Prevalence of Sarcopenia and Its Relationship with Nutritional State and Quality of Life in Patients with Digestive Diseases. Journal of Nutritional Science and Vitaminology, 2018, 64, 445-453.	0.6	22
33	No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma. Liver Cancer, 2018, 7, 359-371.	7.7	29
34	The Relationship between Controlling Nutritional (CONUT) Score and Clinical Markers among Adults with Hepatitis C Virus Related Liver Cirrhosis. Nutrients, 2018, 10, 1185.	4.1	13
35	Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies. BMC Cancer, 2018, 18, 756.	2.6	44
36	Association between sarcopenia and osteoporosis in chronic liver disease. Hepatology Research, 2018, 48, 893-904.	3.4	33

#	Article	IF	Citations
37	Wisteria floribunda agglutininâ€positive human Macâ€⊋ binding protein in decompensated cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1889-1896.	2.8	6
38	Chapter 1 Definitions and diagnosis of sarcopenia. Geriatrics and Gerontology International, 2018, 18, 7-12.	1.5	33
39	Lâ€Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis. Hepatology Communications, 2018, 2, 910-922.	4.3	67
40	Prognostic value of subcutaneous adipose tissue volume in hepatocellular carcinoma treated with transcatheter intra-arterial therapy. Cancer Management and Research, 2018, Volume 10, 2231-2239.	1.9	21
41	Extracellular Water to Total Body Water Ratio in Viral Liver Diseases: A Study Using Bioimpedance Analysis. Nutrients, 2018, 10, 1072.	4.1	42
42	Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma. PLoS ONE, 2018, 13, e0198812.	2.5	51
43	Increase in the skeletal muscle mass to body fat mass ratio predicts the decline in transaminase in patients with nonalcoholic fatty liver disease. Journal of Gastroenterology, 2019, 54, 160-170.	5.1	20
44	Validity of Japanese version of SARCâ€F questionnaire in patients with chronic liver disease. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 947-953.	2.8	17
45	Reduced handgrip strength is predictive of poor survival among patients with liver cirrhosis: A sexâ€stratified analysis. Hepatology Research, 2019, 49, 1414-1426.	3.4	51
46	Slow walking speed overlapped with low handgrip strength in chronic liver disease patients with hepatocellular carcinoma. Hepatology Research, 2019, 49, 1427-1440.	3.4	22
47	Prognostic Significance of Sarcopenia in Patients with Unresectable Advanced Esophageal Cancer. Journal of Clinical Medicine, 2019, 8, 1647.	2.4	18
48	Rapid Depletions of Subcutaneous Fat Mass and Skeletal Muscle Mass Predict Worse Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib. Cancers, 2019, 11, 1206.	3.7	38
49	Impact of Preoperative Skeletal Muscle Quality Measurement on Longâ€Term Survival After Curative Gastrectomy for Locally Advanced Gastric Cancer. World Journal of Surgery, 2019, 43, 3083-3093.	1.6	27
50	Significant Correlation Between Grip Strength and m2bpgi in Patients with Chronic Liver Diseases. Journal of Clinical Medicine, 2019, 8, 1359.	2.4	5
51	Association between Albumin-Bilirubin Grade and Non-Protein Respiratory Quotient in Patients with Chronic Liver Diseases. Journal of Clinical Medicine, 2019, 8, 1485.	2.4	1
52	Body Composition Is an Independent Predictor of Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib. Liver Cancer, 2019, 8, 255-270.	7.7	30
53	Clinical and pathological features of sarcopeniaâ€related indices in patients with nonâ€alcoholic fatty liver disease. Hepatology Research, 2019, 49, 627-636.	3.4	16
54	Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy. PLoS ONE, 2019, 14, e0218136.	2.5	15

#	Article	IF	CITATIONS
55	Diabetes in Liver Disease. , 2019, , 65-86.		0
56	Combined Albumin-Bilirubin Grade and Skeletal Muscle Mass as a Predictor in Liver Cirrhosis. Journal of Clinical Medicine, 2019, 8, 782.	2.4	12
57	Association between Sarcopenia and Depression in Patients with Chronic Liver Diseases. Journal of Clinical Medicine, 2019, 8, 634.	2.4	13
58	Preoperative Visceral Adiposity and Muscularity Predict Poor Outcomes after Hepatectomy for Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 92-109.	7.7	80
59	Skeletal muscle volume loss during transarterial chemoembolization predicts poor prognosis in patients with hepatocellular carcinoma. Hepatology Research, 2019, 49, 778-786.	3.4	39
60	Serum Zinc Concentration and Sarcopenia: A Close Linkage in Chronic Liver Diseases. Journal of Clinical Medicine, 2019, 8, 336.	2.4	40
61	Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis. Hepatology Communications, 2019, 3, 348-355.	4.3	43
62	Easy surveillance of muscle volume decline in chronic liver disease patients using fingerâ€circle (<i>yubiâ€wakka</i>) test. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 347-354.	7.3	23
63	Prediction of risk of falls based on handgrip strength in chronic liver disease patients living independently. Hepatology Research, 2019, 49, 823-829.	3.4	16
64	Chronological changes in skeletal muscle mass following livingâ€donor liver transplantation: An analysis of the predictive factors for longâ€term postâ€transplant low muscularity. Clinical Transplantation, 2019, 33, e13495.	1.6	16
65	Serum Zinc Level Classification System: Usefulness in Patients with Liver Cirrhosis. Journal of Clinical Medicine, 2019, 8, 2057.	2.4	10
66	Sarcopenia impairs health-related quality of life in cirrhotic patients. European Journal of Gastroenterology and Hepatology, 2019, 31, 1550-1556.	1.6	21
67	Comparative assessment of sarcopenia using the JSH, AWGS, and EWGSOP2 criteria and the relationship between sarcopenia, osteoporosis, and osteosarcopenia in patients with liver cirrhosis. BMC Musculoskeletal Disorders, 2019, 20, 615.	1.9	56
68	Can l-carnitine supplementation and exercise improve muscle complications in patients with liver cirrhosis who receive branched-chain amino acid supplementation?. European Journal of Gastroenterology and Hepatology, 2019, 31, 878-884.	1.6	23
69	Effect of loop diuretics on skeletal muscle depletion in patients with liver cirrhosis. Hepatology Research, 2019, 49, 82-95.	3.4	31
70	Effect of Sarcopenia on Sleep Disturbance in Patients with Chronic Liver Diseases. Journal of Clinical Medicine, 2019, 8, 16.	2.4	14
71	Risk factors for loss of skeletal muscle mass in patients with cirrhosis. Hepatology Research, 2019, 49, 550-558.	3.4	9
72	Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis. Hepatology Research, 2019, 49, 201-211.	3.4	16

#	Article	IF	CITATIONS
73	Impact of Sarcopenic Obesity on Outcomes in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma. Annals of Surgery, 2019, 269, 924-931.	4.2	121
74	Predictors of Insulin Secretion in Japanese Patients with Histopathologically-confirmed Non-alcoholic Fatty Liver Disease. Internal Medicine, 2020, 59, 329-338.	0.7	1
75	Effect of furosemide on muscle cramps in patients with liver cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 76-81.	2.8	6
76	Skeletal Muscle Mass Index Predicts Postoperative Complications in Intestinal Surgery for Crohn's Disease. Journal of Parenteral and Enteral Nutrition, 2020, 44, 714-721.	2.6	32
77	Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis. Journal of Gastroenterology, 2020, 55, 217-226.	5.1	16
78	Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis. Alimentary Pharmacology and Therapeutics, 2020, 51, 64-77.	3.7	126
79	Relationship between serum vitaminÂD level and sarcopenia in chronic liver disease. Hepatology Research, 2020, 50, 588-597.	3.4	21
80	Sarcopenia is a prognostic factor for TKIs in metastatic thyroid carcinomas. Endocrine, 2020, 68, 132-137.	2.3	10
81	Prevalence of sarcopenia as a comorbid disease: A systematic review and meta-analysis. Experimental Gerontology, 2020, 131, 110801.	2.8	187
82	Clinical utility of the Liver Frailty Index for predicting muscle atrophy in chronic liver disease patients with hepatocellular carcinoma. Hepatology Research, 2020, 50, 330-341.	3.4	19
83	SARCâ \in F combined with a simple tool for assessment of muscle abnormalities in outpatients with chronic liver disease. Hepatology Research, 2020, 50, 502-511.	3.4	11
84	Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients. Liver Cancer, 2020, 9, 148-155.	7.7	27
85	Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with Lenvatinib. Liver Cancer, 2020, 9, 193-206.	7.7	57
86	Prognostic Significance of Sarcopenia in Advanced Biliary Tract Cancer Patients. Frontiers in Oncology, 2020, 10, 1581.	2.8	18
87	Sarcopenia and Frailty in Chronic Liver Damage: Common and Different Points. In Vivo, 2020, 34, 2549-2559.	1.3	8
88	Phase Angle From Bioelectrical Impedance for the Assessment of Sarcopenia in Cirrhosis With or Without Ascites. Clinical Gastroenterology and Hepatology, 2021, 19, 1941-1949.e2.	4.4	39
89	Association between serum irisin concentrations and sarcopenia in patients with liver cirrhosis: a cross-sectional study. Scientific Reports, 2020, 10, 16093.	3.3	30
90	Verification of the Nutritional and Dietary Factors Associated with Skeletal Muscle Index in Japanese Patients with Nonalcoholic Fatty Liver Disease. Canadian Journal of Gastroenterology and Hepatology, 2020, 2020, 1-10.	1.9	6

		CITATION REPORT		
#	Article		IF	Citations
91	Anthropometric Measurements and Frailty in Patients with Liver Diseases. Diagnostics	, 2020, 10, 433.	2.6	9
92	Skeletal muscle volume loss among liver cirrhosis patients receiving levocarnitine pred prognosis. Medicine (United States), 2020, 99, e21061.	icts poor	1.0	4
93	High Salt Diet Impacts the Risk of Sarcopenia Associated with Reduction of Skeletal M Performance in the Japanese Population. Nutrients, 2020, 12, 3474.	uscle	4.1	22
94	Sarcopenia: Clinical implications in ovarian cancer, diagnosis, etiology, and manageme Medicine and Health Science, 2020, 2, 202-210.	nt. Sports	2.0	5
95	Ultrasound for Measuring the Cross-Sectional Area of Biceps Brachii Muscle in Sarcope International Journal of Medical Sciences, 2020, 17, 2947-2953.	nia.	2.5	19
96	Loss of skeletal muscle mass affects the incidence of minimal hepatic encephalopathy: study. BMC Gastroenterology, 2020, 20, 371.	a case control	2.0	7
97	Impact of Grip Strength in Patients with Unresectable Hepatocellular Carcinoma Treate Lenvatinib. Cancers, 2020, 12, 2146.	ed with	3.7	23
98	Molecular Mechanism Contributing to Malnutrition and Sarcopenia in Patients with Liv International Journal of Molecular Sciences, 2020, 21, 5357.	ver Cirrhosis.	4.1	46
99	Frailty and Sleep Disorder in Chronic Liver Diseases. Life, 2020, 10, 137.		2.4	7
100	A significant association of non-obese non-alcoholic fatty liver disease with sarcopenic Clinical Nutrition ESPEN, 2020, 38, 86-93.	obesity.	1.2	23
101	Relationship between Osteosarcopenia and Frailty in Patients with Chronic Liver Disea Clinical Medicine, 2020, 9, 2381.	se. Journal of	2.4	23
102	Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis. International Journal o Sciences, 2020, 21, 5254.	f Molecular	4.1	28
103	Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma un treatments. Journal of Gastroenterology, 2020, 55, 927-943.	dergoing	5.1	70
104	Sarcopenia in Autoimmune and Rheumatic Diseases: A Comprehensive Review. Interna Molecular Sciences, 2020, 21, 5678.	itional Journal of	4.1	62
105	Skeletal-muscle index predicts survival after percutaneous transhepatic biliary drainage obstructive jaundice due to perihilar cholangiocarcinoma. Surgical Endoscopy and Oth Interventional Techniques, 2021, 35, 6073-6080.	e for Ier	2.4	13
106	Urinary titin N-terminal fragment concentration is an indicator of preoperative sarcope nutritional status in patients with gastrointestinal tract and hepatobiliary pancreatic m Nutrition, 2020, 79-80, 110957.	nia and nalignancies.	2.4	5
107	Calf Circumference as a Useful Predictor of Sarcopenia in Patients With Liver Diseases. 34, 2561-2569.	. In Vivo, 2020,	1.3	14
108	Prognostic Impact of Sarcopenic Obesity after Neoadjuvant Chemotherapy Followed b Elderly Patients with Esophageal Squamous Cell Carcinoma. Journal of Clinical Medicin	y Surgery in e, 2020, 9, 2974.	2.4	20

#	Article	IF	CITATIONS
109	Impaired brain function improved by l-carnitine in patients with cirrhosis: evaluation using near-infrared spectroscopy. Scientific Reports, 2020, 10, 13566.	3.3	6
110	Effect of Handgrip Strength on Clinical Outcomes of Patients with Hepatocellular Carcinoma Treated with Lenvatinib. Applied Sciences (Switzerland), 2020, 10, 5403.	2.5	4
111	Computed tomography, not bioelectrical impedance analysis, is the proper method for evaluating changes in skeletal muscle mass in liver disease. JCSM Rapid Communications, 2020, 3, 103-114.	1.6	8
112	Low Serum 25-Hydroxyvitamin D Levels Are Related to Frailty and Sarcopenia in Patients with Chronic Liver Disease. Nutrients, 2020, 12, 3810.	4.1	11
113	Change in skeletal muscle index and its prognostic significance in patients who underwent successful conversion therapy for initially unresectable colorectal cancer: observational study. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482097119.	3.2	3
114	Treatment on the Spleen Prevents the Progression of Secondary Sarcopenia in Patients With Liver Cirrhosis. Hepatology Communications, 2020, 4, 1812-1823.	4.3	5
115	Low Serum Branched-chain Amino Acid and Insulin-Like Growth Factor-1 Levels Are Associated with Sarcopenia and Slow Gait Speed in Patients with Liver Cirrhosis. Journal of Clinical Medicine, 2020, 9, 3239.	2.4	16
116	Is sarcopenic obesity superior to sarcopenia as a predicting indicator in patients with hepatocellular carcinoma following hepatic resection?. Hepatobiliary Surgery and Nutrition, 2020, 9, 202-204.	1.5	1
117	Association of an Overhydrated State With the Liver Fibrosis and Prognosis of Cirrhotic Patients. In Vivo, 2020, 34, 1347-1353.	1.3	6
118	Arm Skeletal Muscle Mass Is Associated With the Prognosis of Patients With Cirrhosis. In Vivo, 2020, 34, 1165-1171.	1.3	6
119	Is there any correlation between liver graft regeneration and recipient's pretransplant skeletal muscle mass?—a study in extended left lobe graft living-donor liver transplantation. Hepatobiliary Surgery and Nutrition, 2020, 9, 183-194.	1.5	11
120	Critical appraisal of papers reporting recommendation on sarcopenia using the AGREE II tool: a EuroAIM initiative. European Journal of Clinical Nutrition, 2020, 74, 1164-1172.	2.9	13
121	Serum Zinc Level Is Associated with Frailty in Chronic Liver Diseases. Journal of Clinical Medicine, 2020, 9, 1570.	2.4	8
122	Health-Related Quality of Life and Frailty in Chronic Liver Diseases. Life, 2020, 10, 76.	2.4	6
123	Reduced dietary omega-3 fatty acids intake is associated with sarcopenia in elderly patients with type 2 diabetes: a cross-sectional study of KAMOGAWA-DM cohort study. Journal of Clinical Biochemistry and Nutrition, 2020, 66, 233-237.	1.4	24
124	Analysis of the optimal psoas muscle mass index cutâ€off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people. Hepatology Research, 2020, 50, 715-725.	3.4	28
125	The Anthropometric Assessment With the Bioimpedance Method Is Associated With the Prognosis of Cirrhotic Patients. In Vivo, 2020, 34, 687-693.	1.3	8
126	Impact of CT-Determined Sarcopenia and Body Composition on Survival Outcome in Patients with Advanced-Stage High-Grade Serous Ovarian Carcinoma. Cancers, 2020, 12, 559.	3.7	28

#	Article	IF	CITATIONS
127	Usefulness of Carnitine Supplementation for the Complications of Liver Cirrhosis. Nutrients, 2020, 12, 1915.	4.1	33
128	Utility of the simplified measurements of muscle mass in patients with gastrointestinal and chronic liver diseases. Scientific Reports, 2020, 10, 10795.	3.3	2
129	Rapid Depletion of Subcutaneous Adipose Tissue during Sorafenib Treatment Predicts Poor Survival in Patients with Hepatocellular Carcinoma. Cancers, 2020, 12, 1795.	3.7	15
130	Relationship between presarcopenia and event occurrence in patients with primary hepatocellular carcinoma. Scientific Reports, 2020, 10, 10186.	3.3	12
131	Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study. Cancer Chemotherapy and Pharmacology, 2020, 86, 129-139.	2.3	10
132	Effect of preâ€ŧransplant sarcopenia on the estimation of standard liver volume in livingâ€donor liver transplant candidates: risk factor for postâ€ŧransplant smallâ€forâ€size syndrome? A retrospective study. Transplant International, 2020, 33, 1282-1290.	1.6	9
133	Close Correlation between Frailty and Depressive State in Chronic Liver Diseases. Medicina (Lithuania), 2020, 56, 319.	2.0	2
134	Calculated body muscle mass as a useful screening marker for low skeletal muscle mass and sarcopenia in chronic liver disease. Hepatology Research, 2020, 50, 704-714.	3.4	8
135	The relationship between sarcopenia and oral sarcopenia in elderly people. Journal of Oral Rehabilitation, 2020, 47, 636-642.	3.0	32
136	Impact of Sustained Virological Response for Gastroesophageal Varices in Hepatitis-C-Virus-Related Liver Cirrhosis. Journal of Clinical Medicine, 2020, 9, 95.	2.4	12
137	Controlling Nutritional Status score does not predict patients' overall survival or hepatocellular carcinoma recurrence after deceased donor liver transplantation. Clinical Transplantation, 2020, 34, e13786.	1.6	7
138	Overestimation of glomerular filtration rate calculated from serum creatinine as compared with cystatin C in patients with subclinical hypercortisolism: Hyogo Adrenal Metabolic Registry. Endocrine Journal, 2020, 67, 469-476.	1.6	9
139	Assessment of Malnutrition, Sarcopenia and Frailty in Patients with Cirrhosis: Which Tools Should We Use in Clinical Practice?. Nutrients, 2020, 12, 186.	4.1	72
140	Walking Speed: Japanese Data in Chronic Liver Diseases. Journal of Clinical Medicine, 2020, 9, 166.	2.4	5
141	Serum Zinc Level and non-Protein Respiratory Quotient in Patients with Chronic Liver Diseases. Journal of Clinical Medicine, 2020, 9, 255.	2.4	0
142	Grip Strength: A Useful Marker for Composite Hepatic Events in Patients with Chronic Liver Diseases. Diagnostics, 2020, 10, 238.	2.6	14
143	The Molar Ratio of Total Branched-chain Amino Acids to Tyrosine Predicts a Digit Symbol Test Abnormality in Cirrhotic Patients. Internal Medicine, 2020, 59, 1695-1704.	0.7	2
144	Frailty Is Associated With Increased Rates of Acute Cellular Rejection Within 3 Months After Liver Transplantation, 2020, 26, 1200-1201.	2.4	1

#	Article	IF	CITATIONS
145	Sarcopenia in chronic liver diseases: a translational overview. Expert Review of Gastroenterology and Hepatology, 2020, 14, 355-366.	3.0	6
146	Impact of Decorin on the Physical Function and Prognosis of Patients with Hepatocellular Carcinoma. Journal of Clinical Medicine, 2020, 9, 936.	2.4	13
147	Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab. Cancer Immunology, Immunotherapy, 2021, 70, 1593-1603.	4.2	32
148	Clinical impact of sarcopenia assessment in patients with liver cirrhosis. Expert Review of Gastroenterology and Hepatology, 2021, 15, 377-388.	3.0	15
149	Impacts of Preoperative Psoas Muscle Mass and Visceral Fat Area on Postoperative Short―and Longâ€Term Outcomes in Patients with Gastric Cancer. World Journal of Surgery, 2021, 45, 815-821.	1.6	28
150	Prevalence and Impact of Sarcopenia in Chronic Pancreatitis: A Review of the Literature. World Journal of Surgery, 2021, 45, 590-597.	1.6	21
151	Validity of measuring psoas muscle mass index for assessing sarcopenia in patients with gynecological cancer. Japanese Journal of Clinical Oncology, 2021, 51, 393-399.	1.3	8
152	Extracellular water to total body water ratio obtained by bioelectrical impedance analysis determines the dose intensity of lenvatinib for the treatment of patients with advanced hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1685-1693.	2.8	5
153	Plasma free amino acids are associated with sarcopenia in the course of hepatocellular carcinoma recurrence. Nutrition, 2021, 84, 111007.	2.4	6
154	Calf and arm circumference as simple markers for screening sarcopenia in patients with chronic liver disease. Hepatology Research, 2021, 51, 176-189.	3.4	21
155	Lenvatinib for Hepatocellular Carcinoma: A Literature Review. Pharmaceuticals, 2021, 14, 36.	3.8	30
156	Predictors for Grip Strength Loss in Patients With Chronic Liver Diseases. In Vivo, 2021, 35, 363-371.	1.3	6
157	Nutrition in Chronic Liver Disease: Consensus Statement of the Indian National Association for Study of the Liver. Journal of Clinical and Experimental Hepatology, 2021, 11, 97-143.	0.9	36
158	U-TEST, a simple decision support tool for the diagnosis of sarcopenia in orthopaedic patients: the Screening for People Suffering Sarcopenia in Orthopedic cohort of Kobe study (SPSS-OK). British Journal of Nutrition, 2021, 126, 1323-1330.	2.3	3
159	Radiologic Definition of Sarcopenia in Chronic Liver Disease. Life, 2021, 11, 86.	2.4	12
160	Decreased Plasma Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) Levels are Linked with Disease Severity in Patients with Liver Cirrhosis. International Journal of Peptide Research and Therapeutics, 2021, 27, 1229-1237.	1.9	2
161	Treatment of Hepatitis C Virus Infection with Direct-acting Antiviral Agents Elevates the Serum Small-dense Low-density Lipoprotein Cholesterol Level. Internal Medicine, 2021, 60, 191-199.	0.7	2
162	Effects of In-Hospital Exercise on Frailty in Patients with Hepatocellular Carcinoma. Cancers, 2021, 13, 194.	3.7	15

#	Article	IF	CITATIONS
163	Factors Associated With Longitudinal QOL Change in Patients With Chronic Liver Diseases. In Vivo, 2021, 35, 2451-2456.	1.3	0
164	Sarcopenia and visceral adiposity predict poor overall survival in hepatocellular carcinoma patients after curative hepatic resection. Translational Cancer Research, 2021, 10, 854-866.	1.0	18
165	Comparison of calculated body muscle mass and SARC‑F as methods of screening for sarcopenia in patients with chronic liver disease. Biomedical Reports, 2021, 14, 34.	2.0	5
166	Sarcopenic Obesity in Liver Cirrhosis: Possible Mechanism and Clinical Impact. International Journal of Molecular Sciences, 2021, 22, 1917.	4.1	25
167	Adipose Tissue Distribution Predicts Prognosis of Cirrhotic Patients Undergoing Hepatectomy for Hepatocellular Carcinoma. Annals of Surgical Oncology, 2021, 28, 6738-6746.	1.5	6
168	Clinical Benefits of Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma. Applied Sciences (Switzerland), 2021, 11, 1882.	2.5	2
169	Efficacy of rifaximin, a poorly absorbed rifamycin antimicrobial agent, for hepatic encephalopathy in Japanese patients. Hepatology Research, 2021, 51, 445-460.	3.4	4
170	Improvement of Skeletal Muscle Mass after Ledipasvir and Sofosbuvir Treatment for Hepatitis C Virus in Decompensated Liver Cirrhosis. Internal Medicine, 2021, 60, 745-750.	0.7	2
171	Branched-chain amino acids and l-carnitine attenuate lipotoxic hepatocellular damage in rat cirrhotic liver. Biomedicine and Pharmacotherapy, 2021, 135, 111181.	5.6	12
172	Alterations of intestinal microbiota in liver cirrhosis with muscle wasting. Nutrition, 2021, 83, 111081.	2.4	16
173	Combined grip strength and calf circumference as a useful prognostic system in patients with liver diseases: a large cohort study. Annals of Translational Medicine, 2021, 9, 624-624.	1.7	6
174	Optimal Skeletal Muscle Mass Index Cut-Off Values for Presarcopenia Evaluated by Computed Tomography against Dual-Energy X-ray Absorptiometry in Patients with Chronic Liver Disease. Journal of Clinical Medicine, 2021, 10, 1419.	2.4	2
175	Sarcopenia and Frailty in Liver Cirrhosis. Life, 2021, 11, 399.	2.4	19
176	Clinical impact of the finger ircle test in patients with liver diseases. Hepatology Research, 2021, 51, 603-613.	3.4	4
177	A significant association of non-obese non-alcoholic fatty liver disease with osteosarcopenic obesity in females 50 years and older. Clinical Nutrition ESPEN, 2021, 42, 166-172.	1.2	6
178	Definition of Sarcopenia in Chronic Liver Disease. Life, 2021, 11, 349.	2.4	13
179	Sarcopenia is related to poor prognosis in patients after trimodality therapy for locally advanced non-small cell lung cancer. International Journal of Clinical Oncology, 2021, 26, 1450-1460.	2.2	4
180	Efficacy of Zinc Acetate Treatment for Patients with Decompensated Liver Cirrhosis Complicated by Hypozincemia. Biological Trace Element Research, 2022, 200, 497-504.	3.5	6

#	Article	IF	CITATIONS
181	Reduced grip strength is associated with progression of depressive status in chronic liver diseases. Annals of Palliative Medicine, 2021, 10, 3976-3987.	1.2	0
182	Presence and Implications of Sarcopenia in Non-alcoholic Steatohepatitis. Metabolites, 2021, 11, 242.	2.9	7
183	Impact of visceral fat accumulation on the prognosis of patients with cirrhosis. Clinical Nutrition ESPEN, 2021, 42, 354-360.	1.2	1
184	Obesity and Liver Cancer in Japan: A Comprehensive Review. Anticancer Research, 2021, 41, 2227-2237.	1.1	5
185	Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma. Cancers, 2021, 13, 2247.	3.7	8
186	Myostatin as a fibroblastâ€activating factor impacts on postoperative outcome in patients with hepatocellular carcinoma. Hepatology Research, 2021, 51, 803-812.	3.4	18
187	Impact of sarcopenia on recurrent biliary obstruction after insertion of selfâ€expandable metallic stent in patients with malignant biliary obstruction. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, 28, 572-580.	2.6	6
188	Evaluation of Muscle Cramp Associated with Liver Cirrhosis with a Focus on the Liver Function and Nutritional Status. Internal Medicine, 2021, 60, 1343-1348.	0.7	2
189	Clinical characteristics of sarcopenia in patients with alcoholic liver cirrhosis. JGH Open, 2021, 5, 763-769.	1.6	6
190	Nutritional assessment tool for predicting sarcopenia in chronic liver disease. JCSM Rapid Communications, 2021, 4, 150-158.	1.6	2
191	Effect of Vitamin D Supplementation on Skeletal Muscle Volume and Strength in Patients with Decompensated Liver Cirrhosis Undergoing Branched Chain Amino Acids Supplementation: A Prospective, Randomized, Controlled Pilot Trial. Nutrients, 2021, 13, 1874.	4.1	10
192	Impact and risk factors for skeletal muscle mass loss after hepatic resection in patients with hepatocellular carcinoma. JCH Open, 2021, 5, 785-792.	1.6	5
193	Impact of preoperative nutritional support and rehabilitation therapy in patients undergoing pancreaticoduodenectomy. International Journal of Clinical Oncology, 2021, 26, 1698-1706.	2.2	21
194	Use of skeletal muscle index as a predictor of short-term mortality in patients with acute-on-chronic liver failure. Scientific Reports, 2021, 11, 12593.	3.3	9
195	Reduced handgrip strength predicts poorer survival in chronic liver diseases: A large multicenter study in Japan. Hepatology Research, 2021, 51, 957-967.	3.4	39
196	Frequency and Characteristics of Overestimated Renal Function in Japanese Patients with Chronic Liver Disease and Its Relation to Sarcopenia. Nutrients, 2021, 13, 2415.	4.1	8
197	Assessment of the association between dysphagia and sarcopenia among elderly patients with cirrhosis: Usefulness of the finger-ring test. Archives of Gerontology and Geriatrics, 2021, 95, 104430.	3.0	2
198	Dynapenia Rather Than Sarcopenia Is Associated with Metabolic Syndrome in Patients with Chronic Liver Diseases. Diagnostics, 2021, 11, 1262.	2.6	5

#	Article	IF	CITATIONS
199	Validity of skeletal muscle mass index measurements for assessing sarcopenia in patients with gynecological cancer. Japanese Journal of Clinical Oncology, 2021, 51, 1534-1540.	1.3	0
200	Evidenceâ€based clinical practice guidelines for liver cirrhosis 2020. Hepatology Research, 2021, 51, 725-749.	3.4	90
201	Sarcopenia—The Impact on Physical Capacity of Liver Transplant Patients. Life, 2021, 11, 740.	2.4	4
202	Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. Journal of Gastroenterology, 2021, 56, 593-619.	5.1	158
203	Prospective study for an independent predictor of prognosis in liver cirrhosis based on the new sarcopenia criteria produced by the Japan Society of Hepatology. Hepatology Research, 2021, 51, 968-978.	3.4	12
204	Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals. Scientific Reports, 2021, 11, 16616.	3.3	6
205	Skeletal Muscle Loss and Octogenarian Status Are Associated with S-1 Adjuvant Therapy Discontinuation and Poor Prognosis after Pancreatectomy. Cancers, 2021, 13, 4105.	3.7	3
206	Influencing Factors and Molecular Pathogenesis of Sarcopenia and Osteosarcopenia in Chronic Liver Disease. Life, 2021, 11, 899.	2.4	15
207	Common musculoskeletal disorders in chronic liver disease patients. Joint Diseases and Related Surgery, 2021, 32, 818-823.	1.0	6
208	Utility of the SARC-F Questionnaire for Sarcopenia Screening in Patients with Chronic Liver Disease: A Multicenter Cross-Sectional Study in Japan. Journal of Clinical Medicine, 2021, 10, 3448.	2.4	10
209	Evaluation of and Intervention for Sarcopenia in Hepatology Departments: A Survey of Nurses in Japan. Healthcare (Switzerland), 2021, 9, 1021.	2.0	2
210	Cancer Cachexia: Its Mechanism and Clinical Significance. International Journal of Molecular Sciences, 2021, 22, 8491.	4.1	86
211	Handgrip strength stratifies the risk of covert and overt hepatic encephalopathy in patients with cirrhosis. Journal of Parenteral and Enteral Nutrition, 2022, 46, 858-866.	2.6	20
212	Prognostic significance of skeletal muscle decrease in unresectable pancreatic cancer: Survival analysis using the Weibull exponential distribution model. Pancreatology, 2021, 21, 892-902.	1.1	10
213	Reliability and Concurrent Validity of the SARC-F and Its Modified Versions: A Systematic Review and Meta-Analysis. Journal of the American Medical Directors Association, 2021, 22, 1864-1876.e16.	2.5	52
214	Evaluation of skeletal muscle mass using prediction formulas at the level of the 12th thoracic vertebra. Nutrition, 2021, 93, 111475.	2.4	1
215	Clinical Usefulness of FRAX Score for Predicting Sarcopenia in Patients with Chronic Liver Disease. Journal of Clinical Medicine, 2021, 10, 4080.	2.4	1
216	Sarcopenia and long-term survival outcomes after local therapy for colorectal liver metastasis: a meta-analysis. Hpb, 2022, 24, 9-16.	0.3	11

#	Article	IF	CITATIONS
217	A simpler screening tool for sarcopenia in surgical patients. PLoS ONE, 2021, 16, e0257672.	2.5	3
218	Women are predisposed to early doseâ€limiting toxicities during adjuvant CAPOX for colorectal cancer. International Journal of Clinical Practice, 2021, 75, e14863.	1.7	2
219	Letter: patients who have both sarcopenia and frailty have similar prognosis to those with either condition separately—authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 983-984.	3.7	1
220	Significance of liver fat loss in chronic liver disease: Usefulness of hepatic proton density fat fraction measurement by magnetic resonance imaging in evaluating malnutrition. Acta Hepatologica Japonica, 2021, 62, 525-537.	0.1	0
221	Usefulness of nutritional therapy recommended in the Japanese Society of Gastroenterology/Japan Society of Hepatology evidence-based clinical practice guidelines for liver cirrhosis 2020. Journal of Gastroenterology, 2021, 56, 928-937.	5.1	7
222	The association between sarcopenia and endotoxin in patients with alcoholic cirrhosis. Medicine (United States), 2021, 100, e27212.	1.0	10
223	Comparison of SARC-F Score among Gastrointestinal Diseases. Journal of Clinical Medicine, 2021, 10, 4099.	2.4	7
224	Clinical and Tumor Characteristics of Patients with High Serum Levels of Growth Differentiation Factor 15 in Advanced Pancreatic Cancer. Cancers, 2021, 13, 4842.	3.7	15
225	Sarcopenia as a prognostic predictor of liver cirrhosis: a multicentre study in China. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 1948-1958.	7.3	59
226	Inflammatory Bowel Disease and Sarcopenia: Its Mechanism and Clinical Importance. Journal of Clinical Medicine, 2021, 10, 4214.	2.4	28
227	Molecular Mechanisms and Treatment of Sarcopenia in Liver Disease: A Review of Current Knowledge. International Journal of Molecular Sciences, 2021, 22, 1425.	4.1	10
228	Liver fibrosis-induced muscle atrophy is mediated by elevated levels of circulating TNFα. Cell Death and Disease, 2021, 12, 11.	6.3	14
229	Assessment of Body Composition From CT Images at the Level of the Third Lumbar Vertebra in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2021, 27, 1435-1442.	1.9	34
230	Effect of branched-chain amino acid supplements on muscle strength and muscle mass in patients with liver cirrhosis. European Journal of Gastroenterology and Hepatology, 2017, 29, 1402-1407.	1.6	36
231	Relationship between pre-sarcopenia and quality of life in patients with chronic liver disease: a cross-sectional study. European Journal of Gastroenterology and Hepatology, 2019, 31, 1408-1413.	1.6	16
232	Relationship between osteoporosis, sarcopenia, vertebral fracture, and osteosarcopenia in patients with primary biliary cholangitis. European Journal of Gastroenterology and Hepatology, 2021, 33, 731-737.	1.6	20
233	Relationship Between Sarcopenia and Both Physical Activity and Lifestyle in Patients With Chronic Liver Disease. Journal of Clinical Medicine Research, 2018, 10, 920-927.	1.2	24
234	Profiles Associated with Sarcopenia in Hepatoma Patients Underwent Transcatheter Arterial Chemoembolization: A Data-Mining Analysis. JCSM Clinical Reports, 2018, 3, .	1.3	4

#	Article	IF	CITATIONS
235	Impact of cancer rehabilitation on the prognosis of patients with hepatocellular carcinoma. Oncology Letters, 2020, 19, 2355-2367.	1.8	20
236	Protein Intake Recommendation for Korean Older Adults to Prevent Sarcopenia: Expert Consensus by the Korean Geriatric Society and the Korean Nutrition Society. Annals of Geriatric Medicine and Research, 2018, 22, 167-175.	1.8	24
237	The Effect of Loop Diuretics on Sarcopenia and Long-Term Prognosis in Patients with Refractory Hepatic Ascites Treated with Tolvaptan. Open Journal of Gastroenterology, 2018, 08, 201-208.	0.1	1
238	Screening Tools for Sarcopenia. In Vivo, 2021, 35, 3001-3009.	1.3	17
239	Sarcopenia, frailty and typeÂ2 diabetes mellitus (Review). Molecular Medicine Reports, 2021, 24, .	2.4	28
240	Metabolic Syndrome and Sarcopenia. Nutrients, 2021, 13, 3519.	4.1	80
241	A comprehensive investigation of nutritional status and psoas muscle mass in predicting five-year survival in patients with liver transplant. Journal of the Formosan Medical Association, 2022, 121, 1317-1324.	1.7	1
242	The Therapeutic Intervention of Sex Steroid Hormones for Sarcopenia. Frontiers in Medicine, 2021, 8, 739251.	2.6	18
243	Sarcopenia Updates in Concept, Diagnosis, and Treatment: Could Medium Chain Triglycerides Be a Treatment Candidate for Sarcopenia?. Oleoscience, 2018, 18, 383-391.	0.0	0
244	Sarcopenia Clinical Practice Guideline 2017 and Rehabilitation. The Japanese Journal of Rehabilitation Medicine, 2018, 55, 410-417.	0.0	0
245	ãfªãfãf"ãfªãf†ãf¼ã, ãf§ãf³ã«ãĚãťã, «ä½"組æ^̀e©•価ã®é‡e¦æ€§. The Japanese Journal of SURGICAL METAE	8O løSi M an	d NUTRITION
246	Efficacy of Physical Activity in Prevention of Muscle Weakness in Patients With Chronic Liver Disease. Journal of Clinical Medicine Research, 2019, 11, 711-719.	1.2	1
247	Sarcopenia in Liver Disease. , 2019, , 119-130.		0
248	Nutrition in Liver Cirrhosis. , 2019, , 69-77.		0
249	The role of muscle depletion and visceral adiposity in HCC patients aged 65 and over undergoing TACE. BMC Cancer, 2021, 21, 1164.	2.6	11
250	Role of L3-PMI in prognostic evaluation of patients with acute-on-chronic liver failure related to hepatitis B cirrhosis. World Chinese Journal of Digestology, 2021, 29, 1167-1173.	0.1	1
251	A case demonstrating the usefulness of levocarnitine supplementation in the management of bimodal fatigue during lenvatinib therapy for advanced hepatocellular carcinoma. Acta Hepatologica Japonica, 2020, 61, 715-721.	0.1	0
252	Indices calculated by serum creatinine and cystatin C as predictors of liver damage, muscle strength and sarcopenia in liver disease. Biomedical Reports, 2020, 12, 89-98.	2.0	12

#	Article	IF	CITATIONS
253	Relationship between sarcopenia and prognosis during the initial period of hemodialysis. Nihon Toseki Igakkai Zasshi, 2020, 53, 235-242.	0.1	0
254	Nutrition support for pancreatic disease and its relationship with sarcopenia. Suizo, 2020, 35, 166-173.	0.1	Ο
255	Risks of Sarcopenia in Patients with Hematological and Oncological Factors who Underwent Hematopoietic Stem Cell Transplantation. The Japanese Journal of Rehabilitation Medicine, 2020, 57, 352-363.	0.0	1
256	Impact of Sarcopenia as a Prognostic Factor on Reductive Hepatectomy for Advanced Hepatocellular Carcinoma. Anticancer Research, 2021, 41, 5775-5783.	1.1	5
257	Myosteatosis as an independent risk factor for mortality after kidney allograft transplantation: a retrospective cohort study. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 386-396.	7.3	14
258	Changes in the Body Composition and Nutritional Status after Long-term Rifaximin Therapy for Hyperammonemia in Japanese Patients with Hepatic Encephalopathy. Internal Medicine, 2020, 59, 2465-2469.	0.7	6
259	The impact of L-branched-chain amino acids and L-leucine on malnutrition, sarcopenia, and other outcomes in patients with chronic liver disease. Expert Review of Gastroenterology and Hepatology, 2021, 15, 181-194.	3.0	9
260	Effect of physical exercise on sarcopaenia in patients with overt hepatic encephalopathy: a study protocol for a randomised controlled trial. BMJ Open Gastroenterology, 2017, 4, e000185.	2.7	0
261	Clinical influence of exercise therapy on sarcopenia in patients with chronic pancreatitis: a study protocol for a randomised controlled trial. BMJ Open Gastroenterology, 2018, 5, e000190.	2.7	2
262	Effect of exercise therapy on sarcopenia in pancreatic cancer: a study protocol for a randomised controlled trial. BMJ Open Gastroenterology, 2018, 5, e000194.	2.7	5
263	Effect of levocarnitine administration in patients with chronic liver disease. Experimental and Therapeutic Medicine, 2020, 20, 94.	1.8	1
264	Prognostic value of low skeletal muscle mass in hepatocellular carcinoma patients treated with sorafenib or lenvatinib: A meta-analysis. EXCLI Journal, 2021, 20, 1-16.	0.7	0
265	Association of serum creatinine-to-cystatin C ratio with skeletal muscle mass and strength in nonalcoholic fatty liver disease in the Iwaki Health Promotion Project. Journal of Clinical Biochemistry and Nutrition, 2022, 70, 273-282.	1.4	6
266	Advances in Liver Rehabilitation. The Japanese Journal of Rehabilitation Medicine, 2021, 58, 1120-1127.	0.0	0
267	Sarcopenia as a prognostic indicator of liver cirrhosis. Journal of Cachexia, Sarcopenia and Muscle, 2021, , .	7.3	15
268	Proposal for new sleep disorder criteria in patients with chronic liver disease: Influence of liverâ€related complications. Hepatology Research, 2022, 52, 364-370.	3.4	7
269	Significance of body composition and perioperative rehabilitation/nutritional therapy in hepatoâ€biliaryâ€pancreatic and transplant surgery. The Japanese Journal of SURGICAL METABOLISM and NUTRITION, 2021, 55, 201-208.	0.1	0
270	Effect of levocarnitine administration in patients with chronic liver disease. Experimental and Therapeutic Medicine, 2020, 20, 1-1.	1.8	7

ARTICLE IF CITATIONS # Effect of Body Composition Change during Neoadjuvant Chemotherapy for Esophageal Squamous Cell 271 2.4 5 Carcinoma. Journal of Clinical Medicine, 2022, 11, 508. Association of physiological reserve measures with adverse outcomes following liver 1.6 transplantation. JGH Open, 2022, 6, 132-138. The importance of body composition assessment for patients with advanced hepatocellular carcinoma 273 2.54 by bioelectrical impedance analysis in lenvatinib treatment. PLoS ONE, 2022, 17, e0262675. Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK 274 Biobank participants. Journal of Hepatology, 2022, 76, 1021-1029. Impact of psoas muscle index assessed by a simple measurement method on tolerability and duration of continued treatment with sorafenib in hepatocellular carcinoma patients. European Journal of 275 2 1.6 Gastroenterology and Hepatology, 2022, 34, 774-781. The Relationship between the SARC-F Score and the Controlling Nutritional Status Score in Gastrointestinal Diseases. Journal of Clinical Medicine, 2022, 11, 582. 2.4 Association Between Frailty or Sarcopenia and Adverse Outcomes in Inflammatory Bowel Disease: A 277 6 Systematic Review. , 2022, 1, 241-250. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma treated with 278 lenvatinib. Medicine (United States), 2022, 101, e28680. Association between Sarcopenia and Omega-3 Polyunsaturated Fatty Acid in Patients with 280 0.8 1 Hepatocellular Carcinoma. JMA Journal, 2022, 5, . Dynamic relationship between surrogates of skeletal muscle mass and MELD-Na score in three cirrhotic patients under cell-free and concentrated ascites reinfusion therapy. BMJ Case Reports, 2022, 15, e247129. Patients with low muscle mass have characteristic microbiome with low potential for amino acid 282 12 3.3 synthesis in chronic liver disease. Scientific Reports, 2022, 12, 3674. Utility of handgrip strength (HGS) and bioelectrical impedance analysis (BIA) in the diagnosis of 2.0 sarcopenia in cirrhotic patients. BMC Gastroenterology, 2022, 22, 159. Clinical Significance of Serum Zinc Levels on the Development of Sarcopenia in Cirrhotic Patients. 284 0.7 4 Cancer Diagnosis & Prognosis, 2022, 2, 184-193. Changes in Body Composition Predict the Time to Treatment Failure of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma: A Pilot Retrospective Study. Nutrition and Cancer, 2022, 74, 3118-3127. Overestimated Renal Function in Patients with Liver Cirrhosis Predicts Poor Prognosis. Hepatology 286 3.4 4 Research, 2022, , . The Relevance in the Neutrophil to Lymphocyte Ratio and the SARC-F Score in Gastrointestinal Diseases. Journal of Clinical Medicine, 2022, 11, 2012. 2.4 288 Grip Strength in Patients with Gastrointestinal Diseases. Journal of Clinical Medicine, 2022, 11, 2079. 2.4 2 Osteosarcopenia in autoimmune cholestatic liver diseases: Causes, management, and challenges. 289 World Journal of Gastroenterology, 2022, 28, 1430-1443.

# 290	ARTICLE Body Composition Changes and Related Factors in Patients with Ulcerative Colitis: A Retrospective Single-Center Study in China. Medical Science Monitor, 2022, 28, e933942.	lF 1.1	CITATIONS 2
291	Serum carnitine as a biomarker of sarcopenia and nutritional status in preoperative gastrointestinal cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 287-295.	7.3	17
292	Levocarnitine Supplementation Suppresses Lenvatinib-Related Sarcopenia in Hepatocellular Carcinoma Patients: Results of a Propensity Score Analysis. Nutrients, 2021, 13, 4428.	4.1	6
293	Preoperative Fall Risk Assessment Score as a Prognostic Factor in Esophageal Cancer Patients after Esophagectomy. Journal of Clinical Medicine, 2021, 10, 5966.	2.4	1
294	Prognostic Impact of the SARC-F Score in Gastrointestinal Advanced Cancers. Cancers, 2022, 14, 10.	3.7	7
295	Body Composition as a Novel Prognostic Biomarker for the Patients with Advanced Hepatocellular Carcinoma. Yamaguchi Medical Journal, 2021, 70, 157-164.	0.1	0
296	Editorial on "ls there any correlation between liver graft regeneration and recipient's pretransplant skeletal muscle mass?― Hepatobiliary Surgery and Nutrition, 2021, 10, 881-883.	1.5	0
297	Clinical Significance of Sarcopenia in Patients with Advanced Hepatocellular Carcinoma Undergoing Sorafenib Treatment. , 2021, 13, 62-67.		1
298	Sarcopenia. Pancreas, 2022, 51, 148-152.	1.1	10
299	Influence of skeletal muscle volume loss during lenvatinib treatment on prognosis in unresectable hepatocellular carcinoma: a multicenter study in Tohoku, Japan. Scientific Reports, 2022, 12, 6479.	3.3	8
305	Clinical influence of exercise therapy on sarcopenia in patients with chronic pancreatitis: a study protocol for a randomised controlled trial. BMJ Open Gastroenterology, 2018, 5, e000190.	2.7	9
306	Effect of exercise therapy on sarcopenia in pancreatic cancer: a study protocol for a randomised controlled trial. BMJ Open Gastroenterology, 2018, 5, e000194.	2.7	7
309	Clinical Importance of Body Composition in Improving Bone Mineral Density of Femoral Neck After Denosumab Therapy in Patients With Rheumatoid Arthritis or Collagen Diseases. In Vivo, 2022, 36, 1468-1476.	1.3	0
310	Management of Systemic Therapies and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma Based on Sarcopenia Assessment. Liver Cancer, 2022, 11, 329-340.	7.7	5
311	The Prognostic Value of Sarcopenia and Myosteatosis in Biliary Tract Cancer After Palliative Treatment With Radiation-Emitting Metallic Stent. Frontiers in Surgery, 2022, 9, 852137.	1.4	1
312	Bioelectrical Impedance Analysis for the Assessment of Body Composition in Sarcopenia and Type 2 Diabetes. Nutrients, 2022, 14, 1864.	4.1	17
313	Clinical impact of body composition on postoperative outcomes during neoadjuvant chemoradiation therapy for distal bile duct cancer. Molecular and Clinical Oncology, 2022, 16, .	1.0	0
314	Survival benefit of Lâ \in carnitine supplementation in patients with cirrhosis. Journal of Parenteral and Enteral Nutrition, 2022, , .	2.6	2

#	Article	IF	CITATIONS
315	Clinical utility of computed tomography-based evaluation of trunk muscles in primary sclerosing cholangitis. Japanese Journal of Radiology, 2022, , .	2.4	1
316	The ratio of creatinine and cystatin C estimated glomerular filtration rates as a surrogate marker in patients with hepatocellular carcinoma undergoing hepatic resection. Journal of Hepato-Biliary-Pancreatic Sciences, 2022, 29, 964-973.	2.6	4
317	Favorable impact of longâ€ŧerm SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5â€year followâ€up study. Hepatology Communications, 2022, 6, 2286-2297.	4.3	20
318	South Asian Working Action Group on SARCOpenia (SWAG-SARCO) – A consensus document. Osteoporosis and Sarcopenia, 2022, 8, 35-57.	1.9	20
319	Cancer, Phase Angle and Sarcopenia: The Role of Diet in Connection with Lung Cancer Prognosis. Lung, 2022, 200, 347-379.	3.3	20
320	Sarcopenic obesity in liver disease: Handling both sides of the penny. , 2022, 1, 42-56.		8
321	Low preoperative psoas muscle mass index is a risk factor for distal cholangiocarcinoma recurrence after pancreatoduodenectomy: a retrospective analysis. World Journal of Surgical Oncology, 2022, 20, .	1.9	1
322	Handgrip strength predicts early postoperative dysphagia after thoracoscopic–laparoscopic esophagectomy in male patients with esophageal cancer. Esophagus, 2022, 19, 586-595.	1.9	2
323	Association between muscle health and patient-reported outcomes after lumbar microdiscectomy: early results. Spine Journal, 2022, 22, 1677-1686.	1.3	6
324	Low Psoas-Muscle index is associated with decreased survival in hepatocellular carcinoma treated with transarterial chemoembolization. Annals of Medicine, 2022, 54, 1562-1569.	3.8	12
325	Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients. JGH Open, 2022, 6, 477-486.	1.6	13
326	Rifaximin enhances the Lâ€́carnitineâ€́mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gutâ€ʻliverâ€ʿmuscle axis. International Journal of Molecular Medicine, 2022, 50, .	4.0	5
327	Factors associated with the progression of myosteatosis in patients with cirrhosis. Nutrition, 2022, 103-104, 111777.	2.4	3
328	A prognostic model of acute-on-chronic liver failure based on sarcopenia. Hepatology International, 2022, 16, 964-972.	4.2	13
329	Mechanism for development of malnutrition in primary biliary cholangitis. World Journal of Meta-analysis, 2022, 10, 81-98.	0.1	4
330	Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients. PLoS ONE, 2022, 17, e0270786.	2.5	1
331	Diagnosis and pathological analysis of sarcopenia in chronic liver disease using liver MRI. Acta Hepatologica Japonica, 2022, 63, 305-318.	0.1	0
332	Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma. World Journal of Hepatology, 2022, 14, 1480-1494.	2.0	0

	Сітат	CITATION REPORT	
#	Article	IF	CITATIONS
333	Usefulness of the Global Leadership Initiative on Malnutrition criteria to predict sarcopenia and mortality inÂpatients with chronic liver disease. Hepatology Research, 2022, 52, 928-936.	3.4	16
334	Surgical Stress Evaluation of Left Lateral Sectionectomy Based on Skeletal Muscle Catabolism. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 0, Publish Ahead of Print, .	0.8	0
335	Sustained Virological Response Is the Most Effective in Preventing Hepatocellular Carcinoma Recurrence after Curative Treatment in Hepatitis C Virus-Positive Patients: A Study Using Decision Tree Analysis. International Journal of Translational Medicine, 2022, 2, 345-354.	0.4	0
336	CT-based skeletal muscle loss for predicting poor survival in patients with hepatocellular carcinoma experiencing curative hepatectomy plus adjuvant transarterial chemoembolization: a preliminary retrospective study. European Journal of Medical Research, 2022, 27, .	2.2	3
337	An improved method to assess skeletal muscle mass in patients with liver cirrhosis based on computed tomography images. Hepatology Research, 2022, 52, 937-946.	3.4	4
338	Decreased appetite is associated with the presence of sarcopenia in patients with cirrhosis. Nutrition, 2022, 103-104, 111807.	2.4	3
339	Muscle mass ratio in male gastric cancer patients as an independent predictor of postoperative complications after minimally invasive distal gastrectomy. Surgical Endoscopy and Other Interventional Techniques, 0, , .	2.4	1
340	Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis. Clinical and Molecular Hepatology, 2022, 28, 876-889.	8.9	8
341	Clinical significance of hepatic fat loss in chronic liver disease: a study using MRI proton density fat fractionation. European Journal of Clinical Nutrition, 0, , .	2.9	0
342	Measurement of skeletal muscle volume is useful for predicting prognosis in patients with liver cirrhosis. European Journal of Gastroenterology and Hepatology, 2022, 34, 1151-1157.	1.6	1
343	The impact of sarcopenia on short- and long-term outcomes of endoscopic submucosal dissection for early gastric cancer. Journal of Gastroenterology, 2022, 57, 952-961.	5.1	5
344	Body composition as a predictor of chemotherapy-related toxicity in pancreatic cancer patients: A systematic review. Frontiers in Oncology, 0, 12, .	2.8	6
345	Preoperative serum brainâ€derived neurotrophic factor as a predictive biomarker for sepsis after livingâ€donor liver transplantation. Hepatology Research, 2023, 53, 72-83.	3.4	5
346	Subcutaneous Fat Thickness of the Lower Limb is Associated with Trunk Muscle Mass in Patients with Hepatocellular Carcinoma: A Simple Assessment for Sarcopenia Using Conventional Ultrasonography. Kurume Medical Journal, 2020, 67, 97-105.	0.1	2
347	The Impact of Sarcopenia, Frailty, and Malnutrition on Further Decompensation. , 2022, , 563-577.		0
348	Prognostic Impact of Ectopic Fat Deposition within Psoas Muscle in Stage IV Gastric Cancer Patients Undergoing Systemic Chemotherapy. Journal of Cancer, 2022, 13, 3477-3484.	2.5	1
349	Impact of sarcopenia in bladder preservation therapy for muscle-invasive bladder cancer patients: a narrative review. Translational Andrology and Urology, 2022, 11, 1433-1441.	1.4	2
350	The prognostic role of controlling nutritional status and skeletal muscle mass in patients with hepatocellular carcinoma after curative treatment. European Journal of Gastroenterology and Hepatology, 2022, 34, 1269-1276.	1.6	5

#	Article	IF	CITATIONS
351	Higher Responsiveness for Women, High Transaminase Levels, and Fat Percentage to Pemafibrate Treatment for NAFLD. Biomedicines, 2022, 10, 2806.	3.2	1
352	The Significance of Zinc in Patients with Chronic Liver Disease. Nutrients, 2022, 14, 4855.	4.1	5
353	Elevated intramuscular adipose tissue content with a high Ishak fibrosis stage (>3) had a negative effect on liver regeneration in cirrhotic patients undergoing portal vein embolization. Kaohsiung Journal of Medical Sciences, 0, , .	1.9	0
354	Age-specific reference values for low psoas muscle index at the L3 vertebra level in healthy populations: A multicenter study. Frontiers in Nutrition, 0, 9, .	3.7	1
356	Association between sarcopenia and prognosis of hepatocellular carcinoma: A systematic review and meta-analysis. Frontiers in Nutrition, 0, 9, .	3.7	10
357	Sarcopenia increases the risk of early biliary infection after percutaneous transhepatic biliary stent placement. Frontiers in Oncology, 0, 12, .	2.8	1
358	Psoas Muscle Index: A Simple and Reliable Method of Sarcopenia Assessment on Computed Tomography Scan in Chronic Liver Disease and its Impact on Mortality. Journal of Clinical and Experimental Hepatology, 2023, 13, 196-202.	0.9	2
359	Sarcopenia is an Independent Prognostic Factor in Patients With Pancreatic Cancer – a Meta-analysis. Academic Radiology, 2023, 30, 1552-1561.	2.5	5
360	Normative cutoffs of muscle mass, muscle strength, and frailty for healthy Indian population. Indian Journal of Gastroenterology, 2022, 41, 591-598.	1.4	4
361	Prognostic impact of sarcopenia in patients with hepatocellular carcinoma treated with PD-1 inhibitor. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482211424.	3.2	4
362	Association between sarcopenia and clinical outcomes in patients with hepatocellular carcinoma: an updated meta-analysis. Scientific Reports, 2023, 13, .	3.3	11
364	Significance of Skeletal Muscle Loss in Liver Hypertrophy in Patients Undergoing Portal Vein Embolization Before Major Hepatectomy: Assessment With Body Composition and Nutritional Indicators. Anticancer Research, 2023, 43, 209-216.	1.1	0
365	Sarcopenia Defined by Psoas Muscle Thickness Predicts Mortality After Transjugular Intrahepatic Portosystemic Shunt. Digestive Diseases and Sciences, 2023, 68, 1641-1652.	2.3	4
366	Skeletal Muscle Loss During Neoadjuvant Chemotherapy Predicts the Incidence of Postoperative Infectious Complications in Esophageal Cancer Patients Undergoing Esophagectomy. Cancer Diagnosis & Prognosis, 2022, 3, 67-74.	0.7	1
367	Association between hospital acquired disability and post-discharge mortality in patients after living donor liver transplantation. BMC Surgery, 2022, 22, .	1.3	0
368	Annual changes in grip strength and skeletal muscle mass in chronic liver disease: observational study. Scientific Reports, 2023, 13, .	3.3	2
369	Impact of Sarcopenia on Non-Alcoholic Fatty Liver Disease. Nutrients, 2023, 15, 891.	4.1	6
370	Relationship between lipid profiles and reduced handgrip strength (dynapenia) in hospitalized patients with cirrhosis. European Journal of Gastroenterology and Hepatology, 2023, 35, 575-582.	1.6	1

#	Article	IF	CITATIONS
371	Impact of skeletal muscle volume on patients with <scp>BCLC stageâ€B</scp> hepatocellular carcinoma undergoing sorafenib therapy. Cancer Medicine, 0, , .	2.8	1
372	Nutritional Management of a Liver Transplant Candidate. Journal of Clinical and Experimental Hepatology, 2023, 13, 878-894.	0.9	1
373	Prognostic significance of sarcopenia and severe vitamin D deficiency in patients with cirrhosis. JGH Open, 2023, 7, 351-357.	1.6	2
374	Sarcopenia and Frailty in Cirrhosis. Medical Clinics of North America, 2023, 107, 589-604.	2.5	4
375	The Geriatric Nutritional Risk Index predicts sarcopenia in patients with cirrhosis. Scientific Reports, 2023, 13, .	3.3	7
376	VII. Nutrition and Exercise Therapies for Liver Cirrhosis. The Journal of the Japanese Society of Internal Medicine, 2022, 111, 50-57.	0.0	0
377	Prognostic impact of osteosarcopenia in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel. Pancreatology, 2023, 23, 275-282.	1.1	4
378	Implication of Skeletal Muscle Loss in the Prognosis of Patients with Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy. Internal Medicine, 2023, 62, 2783-2793.	0.7	2
379	Diet was less significant than physical activity in the prognosis of people with sarcopenia and metabolic dysfunction-associated fatty liver diseases: Analysis of the National Health and Nutrition Examination Survey III. Frontiers in Endocrinology, 0, 14, .	3.5	4
380	The Inter-Organ Crosstalk Reveals an Inevitable Link between MAFLD and Extrahepatic Diseases. Nutrients, 2023, 15, 1123.	4.1	2
381	Clinics in Liver Disease: Update on Nonalcoholic Steatohepatitis. Clinics in Liver Disease, 2023, 27, 275-286.	2.1	2
382	The Systemic Immune Inflammation Index (SII) Combined with the Creatinine-to-Cystatin C Ratio (Cre/CysC) Predicts Sarcopenia in Patients with Liver Cirrhosis Complicated with Primary Hepatocellular Carcinoma. Nutrition and Cancer, 0, , 1-7.	2.0	0
383	Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospective observational study. Supportive Care in Cancer, 2023, 31, .	2.2	3
384	Treatment efficacy of diet and exercise program for fatty liver and pretreatment predictors. Hepatology Research, 2023, 53, 607-617.	3.4	2
385	A systematic review of sarcopenia prevalence and associated factors in people living with human immunodeficiency virus. Journal of Cachexia, Sarcopenia and Muscle, 2023, 14, 1168-1182.	7.3	5
386	Diagnosis of Sarcopenia Using the <scp>L3</scp> Skeletal Muscle Index Estimated From the <scp>L1</scp> Skeletal Muscle Index on <scp>MR</scp> Images in Patients With Cirrhosis. Journal of Magnetic Resonance Imaging, 2023, 58, 1569-1578.	3.4	4
387	Usefulness of the Measurement of Psoas Muscle Volume for Sarcopenia Diagnosis in Patients with Liver Disease. Diagnostics, 2023, 13, 1245.	2.6	3
388	Prevalence of Sarcopenia in Liver Cirrhosis: A Systematic Review and Meta-Analysis. Clinical and Translational Gastroenterology, 2023, 14, e00584.	2.5	8

#	Article	IF	CITATIONS
389	Hemoglobin levels as a surrogate marker of sarcopenia in patients with liver cirrhosis. Hepatology Research, 2023, 53, 713-722.	3.4	2
390	Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease. International Journal of Molecular Sciences, 2023, 24, 7517.	4.1	3
391	Association of Sarcopenia with a Poor Prognosis and Decreased Tumor-Infiltrating CD8-Positive T Cells in Pancreatic Ductal Adenocarcinoma: A Retrospective Analysis. Annals of Surgical Oncology, 2023, 30, 5776-5787.	1.5	1
392	Usefulness of serum creatinine and cystatin C ratio as a screening tool for predicting prognosis in patients with pancreatic cancer. Annals of Gastroenterological Surgery, 2023, 7, 784-792.	2.4	1
393	Simple method for predicting muscle volume loss using geriatric nutritional risk index in hepatocellular carcinoma patients. Journal of Cachexia, Sarcopenia and Muscle, 2023, 14, 1906-1911.	7.3	1
394	Evaluation of muscle strength and quality in North African patients with chronic hepatitis B: A pilot case control study. Libyan Journal of Medicine, 2023, 18, .	1.6	0
395	Sex-specific associations of single metal and metal mixture with handgrip strength: a cross-sectional study among Chinese adults. Environmental Science and Pollution Research, 2023, 30, 66585-66597.	5.3	2
396	Lean nonalcoholic fatty liver disease: Ageâ€dependent differences in pathology, prognosis, and liverâ€related events. Hepatology Research, 2023, 53, 829-843.	3.4	3
397	Association between Body Composition and the Risk of Portopulmonary Hypertension Assessed by Computed Tomography in Patients with Liver Cirrhosis. Journal of Clinical Medicine, 2023, 12, 3351.	2.4	0
398	Is the ECOG-PS similar to the sarcopenia status for predicting mortality in older adults with cancer? A prospective cohort study. Supportive Care in Cancer, 2023, 31, .	2.2	Ο
399	Clucagon-like peptide-1 receptor agonist, semaglutide attenuates chronic liver disease-induced skeletal muscle atrophy in diabetic mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2023, 1869, 166770.	3.8	5
400	Osteosarcopenia predicts poor survival in patients with cirrhosis: a retrospective study. BMC Gastroenterology, 2023, 23, .	2.0	3
401	Accurate SARC-F Score in Patients with Liver Disease. Diagnostics, 2023, 13, 1959.	2.6	0
402	Geriatric nutritional risk index as an easyâ€ŧoâ€use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Hepatology Research, 2023, 53, 1031-1042.	3.4	5
403	The relationship between sarcopenia, multidimensional frailty, and malnutrition cluster and longâ€ŧerm mortality in hospitalized patients with cirrhosis. , 2023, 2, 51-60.		0
405	Combination of psoas muscle mass index and neutrophil-to-lymphocyte ratio as a noninvasive prognostic marker in hepatocellular carcinoma patients undergoing radiofrequency ablation. European Journal of Gastroenterology and Hepatology, 2023, 35, 568-574.	1.6	Ο
406	Sarcopenia in cirrhosis: epidemiology, diagnosis, management and prognosis. Current Opinion in Gastroenterology, 2023, 39, 131-139.	2.3	2
407	Impact of body fat accumulation on metabolic dysfunctionâ€associated fatty liver disease and nonalcoholic fatty liver disease in Japanese male young adults. Hepatology Research, 2023, 53, 691-700.	3.4	5

#	Article	IF	CITATIONS
408	The impact of nutritional status and changes of body composition on the prognosis of metastatic renal cell carcinoma patients. Journal of Medical Investigation, 2023, 70, 80-87.	0.5	2
409	SHRSP5/Dmcr rats fed a high-fat and high-cholesterol diet develop disease-induced sarcopenia as nonalcoholic steatohepatitis progresses. Annals of Anatomy, 2023, 249, 152104.	1.9	0
410	Prognostic and diagnostic anthropometric biomarkers of sarcopenia in a cohort of Egyptian patients with hepatitis C-induced liver cirrhosis. Egyptian Liver Journal, 2023, 13, .	0.6	0
411	Hemoglobin and Endotoxin Levels Predict Sarcopenia Occurrence in Patients with Alcoholic Cirrhosis. Diagnostics, 2023, 13, 2218.	2.6	2
413	Development of predictive score for postoperative dysphagia after emergency abdominal surgery in patients of advanced age. Annals of Gastroenterological Surgery, 0, , .	2.4	0
414	Impact of sarcopenia on biliary drainage during neoadjuvant therapy for pancreatic cancer. Clinical Endoscopy, 2024, 57, 112-121.	1.5	2
415	Factors associated with low skeletal muscle index among patients with Crohn's disease. Revista Da Associaç£o Médica Brasileira, 2023, 69, .	0.7	0
416	The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib. Oncology, 2023, 101, 491-501.	1.9	0
417	Detection of Sarcopenia in Patients with Liver Cirrhosis Using the Bioelectrical Impedance Analysis. Nutrients, 2023, 15, 3335.	4.1	1
418	Malnutrition and inflammation status in nonobese patients with inflammatory bowel disease are associated with nonalcoholic fatty liver disease: a retrospective study. Intestinal Research, 0, , .	2.6	0
419	Importance of gender differences in body composition for liver transplantation and the â€~ <scp>Sarcoâ€Model'</scp> study. Liver International, 0, , .	3.9	0
420	Lenvatinib or Sorafenib Treatment Causing a Decrease in Skeletal Muscle Mass, an Independent Prognostic Factor in Hepatocellular Carcinoma: A Survival Analysis Using Time-Varying Covariates. Cancers, 2023, 15, 4223.	3.7	4
421	Significance of malnutrition defined with Global Leadership Initiative on Malnutrition criteria in patients with hepatocellular carcinoma after hepatic resection. Hepatology Research, 2023, 53, 1235-1248.	3.4	2
422	Variation in skeletal muscle mass among patients with cirrhosis of different <scp>selfâ€identified</scp> race/ethnicity. JGH Open, 0, , .	1.6	0
423	Use of Branched-Chain Amino Acids as a Potential Treatment for Improving Nutrition-Related Outcomes in Advanced Chronic Liver Disease. Nutrients, 2023, 15, 4190.	4.1	1
424	Body Composition Analysis in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease. Nutrients, 2023, 15, 3878.	4.1	2
425	The impact of osteosarcopenia in patients with unresectable or recurrent biliary tract cancer receiving palliative chemotherapy. Japanese Journal of Clinical Oncology, 0, , .	1.3	0
427	Letter: Muscle thickness measurement using ultrasound—A step closer to the use of body composition analysis in the management of inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2023, 58, 729-730.	3.7	0

#	Article	IF	CITATIONS
428	Impact of sarcopenia on the survival of patients undergoing liver transplantation for decompensated liver cirrhosis. Journal of Cachexia, Sarcopenia and Muscle, 2023, 14, 2602-2612.	7.3	0
429	Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma. Frontiers in Nutrition, 0, 10, .	3.7	0
430	Reduced muscle strength is closely linked to computed tomography-defined myosteatosis among inpatients with cirrhosis. Postgraduate Medical Journal, 2023, 100, 12-19.	1.8	1
431	Upper thigh skeletal muscle index predicts outcomes in liver transplant recipients. Annals of Surgical Treatment and Research, 2023, 105, 219.	1.0	1
432	Clinical impact of sarcopenia in early-stage intrahepatic recurrent hepatocellular carcinoma: an association with impaired host immunity. Langenbeck's Archives of Surgery, 2023, 408, .	1.9	1
433	Insulin Resistance: A Marker for Fat-to-Lean Body Composition in Japanese Adults. Nutrients, 2023, 15, 4724.	4.1	1
434	A Low Geriatric Nutritional Risk Index Is Associated with Low Muscle Volume and a Poor Prognosis among Cirrhotic Patients. Medicina (Lithuania), 2023, 59, 2099.	2.0	0
435	Quantitative Association between Computed-Tomography-Based L1 Skeletal Muscle Indices and Major Adverse Clinical Events Following Percutaneous Coronary Intervention. Journal of Clinical Medicine, 2023, 12, 7483.	2.4	0
436	Hepatic steatosis and skeletal muscle alterations during the COVIDâ€19 lockdown in a cohort of patients with chronic liver disease in Japan. Hepatology Research, 2024, 54, 272-283.	3.4	0
437	PIVKA‑II is associated with liver function, bone metabolism, and muscle function in patients with liver disease. Biomedical Reports, 2023, 20, .	2.0	0
438	Association between the Suita Score and Body Composition in Japanese Adults: A Large Cross-Sectional Study. Nutrients, 2023, 15, 4816.	4.1	0
439	Plasma acylcarnitine in elderly Taiwanese: as biomarkers of possible sarcopenia and sarcopenia. BMC Geriatrics, 2023, 23, .	2.7	2
440	Application of Global Leadership Initiative on Malnutrition criteria in patients with liver cirrhosis. Chinese Medical Journal, 2024, 137, 97-104.	2.3	0
441	SARC-F Score: A Quick Bedside Tool to Screen Sarcopenia in Patients With Cirrhosis. Journal of Clinical and Experimental Hepatology, 2024, 14, 101318.	0.9	0
442	Feasibility of using chest computed tomography (CT) imaging at the first lumbar vertebra (L1) level to assess skeletal muscle mass: a retrospective study. PeerJ, 0, 11, e16652.	2.0	0
443	Unraveling the causes of sarcopenia: Roles of neuromuscular junction impairment and mitochondrial dysfunction. Physiological Reports, 2024, 12, .	1.7	0
444	Body Composition in Chronic Liver Disease. International Journal of Molecular Sciences, 2024, 25, 964.	4.1	0
445	Assessment of lower limb muscle strength can predict fall risk in patients with chronic liver disease. Scientific Reports, 2024, 14, .	3.3	0

ARTICLE IF CITATIONS # Skeletal muscle mass and function are affected by pancreatic atrophy, pancreatic exocrine insufficiency and poor nutritional status in patients with chronic pancreatitis. Pancreatology, 2024, 446 1.1 0 24, 197-205. Feasibility of Colorectal Endoscopic Submucosal Dissection in Elderly Patients: The Impact of 447 2.3 Sarcopenia. Digestion, 0, , 1-11. Lenvatinib Exacerbates the Decrease in Skeletal Muscle Mass in Patients with Hepatocellular 450 3.7 0 Carcinoma, Whereas Atezolizumab Plus Bevacizumab Does Not. Cancers, 2024, 16, 442. Prognostic Effect of Sarcopenia in Hepatocellular Carcinoma Patients Targeted with Interventional Therapy Combined with Immunotherapy and Targeted Therapy. Journal of Hepatocellular Carcinoma, 0, Volume 11, 175-189. Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing 453 0.9 0 and Practices. Journal of Clinical and Experimental Hepatology, 2024, 14, 101347. Association of chronic liver disease with bone diseases and muscle weakness. Journal of Bone and 2.7 Mineral Metabolism, 0, , . Osteosarcopenia impacts treatment outcomes for Barcelona Cancer Liver Classification stage A 455 1.6 0 hepatocellular carcinoma. Surgical Oncology, 2024, 53, 102043. The time window for pre-emptive transjugular intrahepatic portosystemic shunt could be extended to 3.2 5 days. Heliyon, 2024, 10, e25824. Skeletal muscle status and survival among patients with advanced biliary tract cancer. International 457 2.2 0 Journal of Clinical Oncology, 2024, 29, 297-308. Effect of Sarcopenia on Swallowing in Patients With Head and Neck Cancer. Otolaryngology - Head and Neck Surgery, 2024, 170, 1331-1337. Prevalence of Malnutrition in Patients with Hepatocellular Carcinoma: AÂComparative Study of GLIM Criteria, NRS2002, and PG-SGA, and Identification of Independent Risk Factors. Nutrition and Cancer, 459 0 2.0 2024, 76, 335-344. Impact of electrical muscle stimulation on serum myostatin level and maintenance of skeletal muscle mass in patients undergoing livingâ€donor liver transplantation: Singleâ€center controlled trial. 460 3.4 Hepatology Research, Ŏ, , . Impact of Skeletal Muscle Depletion on Patients with Myelodysplastic Syndrome Treated with 461 0.8 0 Azacitidine. Hematology Reports, 2024, 16, 114-124. Ophiocephalus striatus Extract Supplementation Decreases Serum IL-6 Levels in Older People with 1.7 Sarcopeniaâ€"A Single-Center Experience. Geriatrics (Switzerland), 2024, 9, 35. Advanced liver fibrosis is associated with decreased gait speed in older patients with chronic liver 463 3.3 0 disease. Scientific Reports, 2024, 14, .